5
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Efectividad cemiplimab en el cáncer de células escamosas, a propósito de un caso Translated title: Cemiplimab effectiveness in squamous cell cancer, a case report

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Resumen Cemiplimab ha mostrado una actividad antitumoral sustan- terapia sistémica convencional. Presentamos un caso clínico cial en pacientes con carcinoma cutáneo de células escamo- de la seguridad y la actividad antitumoral de cemiplimab en sas. Los pacientes con carcinoma epidermoide cutáneo un paciente con carcinoma epidermoide cutáneo locallocalmente avanzado tienen un pronóstico precario con la mente avanzado.

          Translated abstract

          Abstract Cemiplimab has shown substantial anntitumor activity in patients with cutaeous squamous cell carcinoma. Patients with locally advanced cutaneous squamous cell carcinoma have a por prognosis with conventional systemic therapy. We present a case report of the safety and antitumor activity of cemiplimab in a patient with locally advanced cutaneous squamous cell carcinoma.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: not found
          • Article: not found

          Tumor Mutational Burden and Response Rate to PD-1 Inhibition

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

            No systemic therapies have been approved for the treatment of advanced cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, because the mutation burden of the tumor is high and the disease risk is strongly associated with immunosuppression. In the dose-escalation portion of the phase 1 study of cemiplimab, a deep and durable response was observed in a patient with metastatic cutaneous squamous-cell carcinoma.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

              Cemiplimab has shown substantial antitumour activity in patients with metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous squamous cell carcinoma have poor prognosis with conventional systemic therapy. We present a primary analysis of the safety and antitumour activity of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma.
                Bookmark

                Author and article information

                Journal
                ofil
                Revista de la OFIL
                Rev. OFIL·ILAPHAR
                Organización de Farmacéuticos Ibero-Latinoamericanos (Madrid, Madrid, Spain )
                1131-9429
                1699-714X
                June 2023
                : 33
                : 2
                : 212-213
                Affiliations
                [1] Almería orgnameHospital Universitario Torrecárdenas orgdiv1Servicio de Farmacia España
                [2] Almería orgnameHospital Universitario Torrecárdenas orgdiv1Servicio de Oncología España
                Article
                S1699-714X2023000200017 S1699-714X(23)03300200017
                10.4321/s1699-714x2023000200017
                298f7d5f-068d-4df3-b3c0-ac587f53ee65

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                : 04 September 2021
                : 10 October 2021
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 11, Pages: 2
                Product

                SciELO Spain

                Categories
                Casos Clínicos

                anti-PDL1,oncología,Immunotherapy,Inmunoterapia,oncology
                anti-PDL1, oncología, Immunotherapy, Inmunoterapia, oncology

                Comments

                Comment on this article